BRUSSELS, Belgium, April 04, 2022 (GLOBE NEWSWIRE) --
Summary:
Medi-Tech Insights: The Single-Cell Analysis market growth is driven by growing life science and oncology research.
Description:
Single-cell technologies enable the analysis of differences between individual cells instead of the averaged signal obtained is the case of bulk samples.
Single-cell analysis: A potential oncology research tool
Single-cell analysis is emerging as powerful tool for cancer research. It characterizes the molecular state of each tumor cell, enabling exploration of tumor heterogeneity, microenvironment cell-type composition, and cell state transitions that affect therapeutic response, particularly in the context of immunotherapy. With the growing prevalence of various types of cancers and rising cancer research projects, the demand for products used in single-cell analysis is likely to grow.
“Bulk sequencing can explain the most common mutations in tumor, but single-cell DNA multi-omics offer insights on which mutations occur at single-cell level. Drug developers are increasingly using single-cell analysis to prioritize targets and pathways for new therapies, demonstrate therapeutic efficacy, and understand resistance mechanisms” – Global Research Head, Leading Pharmaceutical Company
Investor funding is providing impetus for single-cell technology
Single-cell analysis has emerged as an important tool for scientific research. Citing the growth potential, investors are funding companies who are developing products/solutions for single-cell analysis. For instance, in November 2021, Singleron Biotechnologies, a start-up company developing single-cell multi-omics products – raised $100 million to ramp up products development and augment international presence. Further, in October 2021, Sphere Fluidics received $40 million to expand international sales activities for its single-cell analysis systems that use proprietary picodroplet technology.
Analysis of complex and richer datasets may present challenge
Single-cell sequencing methods generate more complex and richer datasets compared to bulk sequencing. This higher complexity may lead to misinterpretations and deriving wrong conclusions. However, these challenges are being increasingly addressed with advancements in data analytics as well as use of machine learning/AI in data analysis.
Regional Adoption: Single-Cell Analysis Market
Comprehensive regional assessment of the global single-cell analysis market suggests that US is currently the largest market for single-cell analysis. The U.S. comprises large number of biotech companies as well as research institutes and enjoys greater funding for life science research. Also, the U.S. led global VC investment in biotech sector in 2020, followed by Europe and China. The Asia-Pacific single-cell analysis market led by China is growing faster compared to other regions.
Some of the key players in single-cell analysis market are Becton, Dickinson and Company, Danaher, Merck, Thermo Fisher, Qiagen, 10X Genomics, Fluidigm, Promega, Illumina, Bio-Rad Laboratories, and Luminex.
Detailed Insights on Single-Cell Analysis market @ https://meditechinsights.com/single-cell-analysis-market/
About Us:
Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have successfully completed 100+ projects in Digital Health, Healthcare IT, Medical Devices & Pharma Services.
Contact Us:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
info@meditechinsights.com
